Local NAID (Benzydamin)
PreclinicalSmall molecule
Local NAID (Benzydamin) is one of 17 small molecule programs targeting Tonsillitis. It is currently in Preclinical.
1
Indications
1
Total Trials
0
Active Trials
16
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
21 competitors in Tonsillitis
#DrugCompanyPhaseTrials
1Zofran
NovartisApproved
Amoxil
GGlobal Antibiotics Research and Development Partnership
Approved
Oruvail
WWyeth-Lederle Vaccines
Approved
Zithromax
PPfizer's Upjohn has merged with Mylan to form Viatris Inc.
Approved
Decadron
AAspen Global Incorporated
Approved
Celebrex
PPhiladelphia Eye Associates
Approved
MS Contin
HHikma Pharmaceuticals LLC
Approved
Tylenol
KKenvue Brands
Approved
Versed
CConrado Roberto Hoffmann Filho
Approved
Ketek
SanofiPhase 3
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Tonsillitis1 trial
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Local NAID (Benzydamin). EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details